Clinical Trials Logo

Clinical Trial Summary

Compare the therapeutic utility of SPIES assisted TURB with WLI assisted TURB in patients with non-muscle invasive bladder cancer.


Clinical Trial Description

Urothelial carcinoma of the bladder is the 2nd most common urological malignancy. The vast majority of newly diagnosed cases are non-muscle invasive bladder cancers (NMIBC), which represent about 75%, and it can be treated with transurethral resection (TURBT). The goal of TURBT in Ta and T1 NMIBC is to make the correct diagnosis and completely remove all visible lesions. The quality of TURBT strongly determines patient prognosis and overall treatment.

White light cystoscopy (WLC) remains despite of its limitations the cornerstone of the diagnosis and subsequent treatment of NMIBC. The sensitivity and specificity of WLC range from 62% to 84% and 43% to 98%, respectively. Its sensitivity is lower for small papillary bladder tumors and carcinoma in situ (CIS). Moreover, the accuracy of WLC has been shown to be operator dependent.

Smaller or satellite tumors can be missed, which contributes to almost 40% rate of residual bladder cancer found at the time of 'second-look' TUR. Indistinct borders and difficult visualization of submucosal tumor margins during TUR can lead to incomplete tumor resection and understaging of bladder cancer and leads to tumor recurrence which range from 15% to 61% at one year after surgery based on combined analysis of seven EORTC studies. 3 Non-papillary and flat malignant lesions such as carcinoma in situ (CIS) can be difficult to differentiate from inflammation, with detection rates of CIS only 58% to 68% by WLC.

Fluorescence cystoscopy also known as blue light cystoscopy or photodynamic diagnosis (PDD) requires preoperative intravesical administration of protoporphyrin IX precursor as the contrast agent, a blue light source that illuminates at 375 to 440 nm. Protoporphyrin accumulates preferentially in neoplastic cells and emits fluorescence in the red part of the spectrum under blue light excitation. Though PDD also does not distinguish high-grade from low-grade bladder cancer, PDD has an increased rate of detection of flat appearing CIS vs WLC (87% vs 75% pooled sensitivity; P= .006).

The recurrence rate of PDD-guided TUR of bladder tumor is a matter of controversy. In a meta-analysis of prospective studies on 1345 patients with overall 12 months recurrence rate was significantly lower with PDD compared with WLC (34.5% vs 45.4% pooled sensitivity; P=0.006). However, a prospective randomized multi-institutional trial found no difference in tumor recurrence and progression between PDD and WLC.

Narrow band maging (NBI) devices filter out the red spectrum from white light, with the resultant blue (415 nm) and green (540 nm) spectra absorbed by hemoglobin, thus highlighting the contrast between capillaries and mucosa with no significant difference in detection rate of bladder tumor between new and experienced users. Under NBI, the more vascularized CIS or tumor areas are accentuated in appearance as green or brown. However visibility of NBI cystoscopy is reduced with bleeding or inflammation, due to the strong absorption of light by hemoglobin. In contrast to PDD, systems integrating WLC and NBI are already available. In a recent meta-analysis of 8 studies including 1022 patients, the detection of bladder cancer was higher by NBI compared with WLC on a per-person basis (94% vs 85% pooled sensitivity) and a per-lesion basis (95% vs 75% pooled sensitivity); however, the pooled specificity on a per-lesion basis was lower by NBI compared with WLC (55% vs 72%).

Similar to PDD, NBI does not distinguish bladder cancer grade. The detection of CIS was significantly improved by NBI over WLC (100% vs 83% sensitivity) in a study of 427 patients. Another multicenter, prospective study reported a significantly increased sensitivity for the detection of CIS from 50% for WLC to 90% for NBI in 104 patients. In a recent, single-center, randomized, controlled trial to assess whether NBI improved TUR of bladder tumors in 254 patients with 2-year follow-up, a reduced recurrence rate (22% vs 33%; P=.05) and improved recurrence-free survival (22 vs 19 months; P =.02) were reported by NBI compared with WLC.

Storz Professional Image Enhancement System (SPIES) offers several image enhancement modalities: Spectra A mode is based mainly on the green (~500-570 nm) and blue (~400-480 nm) light spectral signals that are separated in the (Red-Green-Blue) of the camera system within these bands the hemoglobin absorption is significantly higher compared to the red spectral band above 570 nm. Due to the limited penetration depth in the blue to green spectral part, this mode allows to highlight the contrast of capillaries and vessels in the superficial mucosa and submucosa. The SPIES Spectra B pronounces as well as the Spectra A mode the blue to green spectral part in order to reach a higher contrast in the superficial mucosa and sub mucosa. However SPECTRA B is obtained by adding 15% of red colour to SPECTRA A. The Chroma modality enhance the sharpness of the image. The Clara modality create a clearer image of darker regions within the image. Together they should provide a clearer and sharper image of the original WL image.

SPIES enhances the blue and the green wavelengths of the transmitted image and a three-colour image is built from these components of the spectral input. This effect is achieved by suppression of the red portion of the spectrum. By adding different colours to the blue- and green-coloured image (e.g. orange or violet), three types of SPIES images are produced, giving the surgeon three different options for visualization. SPIES proposes the option to choose the best enhancement method in different clinical situations, e.g. SPIES A or C mode, if high contrast is desired or SPIES B mode in case of visual interferences during cystoscopy as hematuria. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03138824
Study type Interventional
Source Mansoura University
Contact
Status Active, not recruiting
Phase N/A
Start date May 15, 2017
Completion date May 1, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03039413 - Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy Early Phase 1
Active, not recruiting NCT03601455 - Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer Phase 2
Completed NCT02989064 - MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers Phase 1
Terminated NCT00072137 - Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Phase 1
Withdrawn NCT05564416 - Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Phase 2
Recruiting NCT04570410 - Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma Phase 2
Recruiting NCT06167356 - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated NCT03266900 - A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival Early Phase 1
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Active, not recruiting NCT03473730 - Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer Early Phase 1
Recruiting NCT05788484 - A Study of CDX-585 in Patients With Advanced Malignancies Phase 1
Recruiting NCT05669430 - A Study of GV20-0251 in Patients With Solid Tumor Malignancies Phase 1
Active, not recruiting NCT04216290 - A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study) Phase 2
Recruiting NCT06416319 - Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct) N/A
Active, not recruiting NCT03775265 - Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Phase 3
Not yet recruiting NCT06263153 - Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Phase 2
Completed NCT00238420 - Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Phase 1/Phase 2
Active, not recruiting NCT02496208 - Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Phase 1
Recruiting NCT04985604 - Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Phase 1/Phase 2